Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Hongzeng
NCT04711148: A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis	Active, not recruiting	2	160	Europe, US, RoW	placebo, orelabrutinib	Beijing InnoCare Pharma Tech Co., Ltd.	Relapsing Remitting Multiple Sclerosis	02/26	03/26